ReviewEULAR rheumatology open2026
Immunometabolism and rheumatic disease-advancing targeted therapies.
Review in EULAR rheumatology open, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
Abstract
Because so many pathways of intermediary metabolism are shared between immune cells and those essential for mammalian life, the possibility of targeting immunometabolism to treat rheumatic diseases long seemed fraught with risk. However, the discovery that targeting receptor-ligand interactions of general importance in immunity (for instance, inflammatory cytokines such as tumour necrosis factor alpha could yield favourable therapeutic windows revolutionised the treatment of inflammatory rheumatic diseases. This synopsis will first define 2 distinct but partially overlapping meanings of immunometabolism. Next, evidence of successes-already achieved or emerging-will be reviewed. Finally, a selected set of research results that offer hopes of future targeting of therapies will be presented.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.